Australia's largest stock trading and investment forum Australia's #1 stock forum

MSB mesoblast limited

38.3%

$2.48

Cell Therapy News/Articles, page-5486

First 5486 Last

Share
Profile

Follow
hubbabubba

105 Posts.

50

07/08/20

10:31

Post #: 46371049
Share

Originally posted by Tunnah: ↑

Morning All!,

Just a bit of an update from the Dr Collins blog this morning with regards to the Eli Lilly Treatment clinical trial (which I still think is pretty substantial news regarding the use of natural body cells to fight the disease instead of "drugs"!)
"Among the most exciting approaches are monoclonal antibodies (mAbs), which are biologic drugs derived from neutralizing antibodies isolated from people who’ve survived COVID-19. This week, the partnership launched two trials (one for COVID-19 inpatients, the other for COVID-19 outpatients) of a mAB called LY-CoV555, which was developed by Eli Lilly and Company, Indianapolis, IN. It was discovered by Lilly’s development partner AbCellera Biologics Inc. Vancouver, Canada, in collaboration with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). In addition to the support from ACTIV, both of the newly launched studies also receive support for Operation Warp Speed, the government’s multi-agency effort against COVID-19.

LY-CoV555 was derived from the immune cells of one of the very first survivors of COVID-19 in the United States. It targets the spike protein on the surface of SARS-CoV-2, blocking it from attaching to human cells.

The first trial, which will look at both the safety and efficacy of the mAb for treating COVID-19, will involve about 300 individuals with mild to moderate COVID-19 who are hospitalized at facilities that are part of existing clinical trial networks. These volunteers will receive either an intravenous infusion of LY-CoV555 or a placebo solution. Five days later, their condition will be evaluated. If the initial data indicate that LY-CoV555 is safe and effective, the trial will transition immediately—and seamlessly—to enrolling an additional 700 participants with COVID-19, including some who are severely ill.

The second trial, which will evaluate how LY-CoV555 affects the early course of COVID-19, will involve 220 individuals with mild to moderate COVID-19 who don’t need to be hospitalized. In this study, participants will randomly receive either an intravenous infusion of LY-CoV555 or a placebo solution, and will be carefully monitored over the next 28 days. If the data indicate that LY-CoV555 is safe and shortens the course of COVID-19, the trial will then enroll an additional 1,780 outpatient volunteers and transition to a study that will more broadly evaluate its effectiveness.

Both trials are later expected to expand to include other experimental therapies under the same master study protocol. Master protocols allow coordinated and efficient evaluation of multiple investigational agents at multiple sites as the agents become available. These protocols are designed with a flexible, rapidly responsive framework to identify interventions that work, while reducing administrative burden and cost.In addition, Lilly this week started a separate large-scale safety and efficacy trial to see if LY-CoV555 can be used to prevent COVID-19 in high-risk residents and staff at long-term care facilities. The study isn’t part of ACTIV."

As another reminder, here is the NIH Article on Interaction between Mesenchymal Stem Cells and B-Cells. Its not a puff piece. I see it as a very respectable neutral study showing both good and bad effects. As mentioned here previously, in studies it has shown that convalescent plasma also works well with MSC's. I can see why natural body cells have the best chance to fight a virus and in my opinion why we have a great fighting chance to treat this thing.

From the NIH Article
The interaction between MSCs and B-cells is sophisticated; diverse culture environments and types of cells affect the immunoregulation of B-cells by MSCs. In purified B-cell–MSC environments, MSCs regulate B-cell functions via soluble factors (Table 1) and cell–cell contact. We found that the soluble factors related to the immunoregulation of B-cells can be divide into two subtypes based on their function: pro-inflammatory and anti-inflammatory. Membrane vesicles, CCL2, B7-H1, VEGF, C3, GAL-9, and IDO are anti-inflammatory, whereas BAFF, PGE2, and APRIL are pro-inflammatory. In the co-culture systems listed above, the B-cell stimulators and the ratio between MSCs and B-cells were varied, yet MSCs were still able to modulate the functions of B-cells. Therefore, this process likely depends on paracrine signaling [96]. We hypothesize that MSCs are influenced by diverse stimulators in co-culture systems, which can lead to the distinct immune regulation of B-cells by MSCs observed in different experimental setups

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881476/
https://directorsblog.nih.gov/2020/08/06/charting-a-rapid-course-toward-better-covid-19-tests-and-treatments/

@Zenox Cheers. for the disclaimer. edited it a bit also Disclaimer: This is NOT financial advice. Do your own research. I am not a financial advisor and under no circumstances should you use any of the information contained in this post for investment purposes. I don't hold a medical degree. I don't even hold a diploma. I like memes and dogs.

Expand

Thanks Tunnah for all your hardwork. I absolutely love your contributions.

My read on what is happening isthat it’s all about T-Cells. More specifically Regulatory T cell memory or “MemoryT Cells”. To me, these will be present in the Convalescent Plasma of Coronavirussurvivors – hence the large focus on this therapy.

More importantly for us, MSCscan help signal the activation of these Memory T-Cells in the body. My interpretationis that Convalescent Plasma Transfusions will be the Gold Standard for themasses and our MSCs will be used in the event that the patient’s condition getsworse. Remestemcel-l seems to work best when the patient’s condition is moresevere. By having the Convalescent Plasma transfusion up front, they will havemore chance of survival as our Therapy will be more effective.

Why have do I have this view?

Tonly Fauci focused on thisduring the US House of Representatives hearing into the Coronavirus response.Go to the 1 hour 41 minute mark. He seems very excited about this.

https://www.youtube.com/watch?v=mO4ERWZYy9I

Then our Dear Donald Trump triesto explain Blood Plasma therapy. He does say that Blood Plasma (I keep thinkingof the Austin Powers ”Liquid Magma” skit) is “not the whole answer, but it’s afantastic part of the puzzle”. I suspect Fauci has briefed him.

Also, the NIH, as led by theMount Sinai Health system quickly focused attention on Convalescent Plasma therapysoon after our EAP for Remestemcel-l in 12 patients back in April.

Then, of course, we have the proposed3-pronged approach in Argentina……

An Argentinian Proposal: Mesenchymal Stem Cells,Convalescent Plasma And Dexamethasone In Covid-19. Could Be A Triple StrategyEffective For The Treatment Of Severe Pneumonia Complications?

https://www.heraldopenaccess.us/openaccess/an-argentinian-proposal-mesenchymal-stem-cells-convalescent-plasma-and-dexamethasone-in-covid-19-could-be-a-triple-strategy-effective-for-the-treatment-of-severe-pneumonia-complications

MSB Price at posting: $4.34 Sentiment: Buy Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Trigg; Droneshield; Lumos & more

STN

Saturn brings up seventh straight Apollo Hill upgrade on 'impressive' 300-hole drill run

DRO

History repeats for DroneShield investors but carnage so far subdued

PSC

Prospect's Mumbezhi Project puts it at the middle of copper's megatrend. And FQM just bought in

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

First 5486 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.48		Change 0.685(38.3%)		Mkt cap ! $3.020B

Open	High	Low	Value	Volume
$1.90	$2.48	$1.90	$42.76M	19.07M

Buyers (Bids)

No.	Vol.	Price($)
6	3102	$2.47

Sellers (Offers)

Price($)	Vol.	No.
$2.48	71803	26

View Market Depth

No.	Vol.	Price($)
6	1998	2.470
18	55098	2.460
14	77015	2.450
14	85835	2.440
13	76662	2.430

Price($)	Vol.	No.
2.480	71801	26
2.490	200866	31
2.500	236342	37
2.510	330376	8
2.520	31485	7

Last trade - 13.40pm 18/07/2025 (20 minute delay)

MSB (ASX) Chart